D. Kalonji

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

D. Moodley, S. Madhi, V. Shinde, 2022, The Lancet HIV.

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

S. Delany-Moretlwe, J. Hughes, B. G. Mirembe, 2022, The Lancet.

The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence

Ashley J. Mayo, J. Baeten, A. van der Straten, 2021, AIDS and Behavior.

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults

M. Andrasik, J. Kublin, M. McElrath, 2021, The New England journal of medicine.

Health system challenges affecting HIV and tuberculosis integration at primary healthcare clinics in Durban, South Africa

O. Mahomed, D. Kalonji, 2019, African journal of primary health care & family medicine.

Cabotegravir for Prevention of HIV-1 in Women: Results From HPTN 084, a Phase III, Randomised Controlled Trial

S. Delany-Moretlwe, J. Hughes, M. Moorhouse, 2022, SSRN Electronic Journal.

Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa

M. Andrasik, L. Bekker, Yunda Huang, 2023, AIDS and Behavior.